NUVB vs. ESPR
NUVB (Nuvation Bio Inc.) and ESPR (Esperion Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, NUVB returned -17.37%/yr vs -31.52%/yr for ESPR. At a 0.29 correlation, their price movements are largely independent.
Performance
NUVB vs. ESPR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NUVB achieves a -47.32% return, which is significantly lower than ESPR's -15.14% return.
NUVB
- 1D
- -3.67%
- 1M
- 7.03%
- YTD
- -47.32%
- 6M
- -43.61%
- 1Y
- 92.65%
- 3Y*
- 40.28%
- 5Y*
- -17.37%
- 10Y*
- —
ESPR
- 1D
- 0.00%
- 1M
- 0.64%
- YTD
- -15.14%
- 6M
- -16.93%
- 1Y
- 199.05%
- 3Y*
- 32.17%
- 5Y*
- -31.52%
- 10Y*
- -15.52%
NUVB vs. ESPR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
NUVB Nuvation Bio Inc. | -47.32% | 236.84% | 76.16% | -21.35% | -77.41% | -27.35% | 17.00% |
ESPR Esperion Therapeutics, Inc. | -15.14% | 68.18% | -26.42% | -52.01% | 24.60% | -80.77% | -16.61% |
Correlation
The correlation between NUVB and ESPR is 0.30, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.30 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.30 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.32 |
Correlation (All Time) Calculated using the full available price history since Aug 25, 2020 | 0.29 |
Fundamentals
NUVB:
$1.78B
ESPR:
$789.25M
NUVB:
-$0.42
ESPR:
-$0.03
NUVB:
11.59
ESPR:
1.75
NUVB:
$143.05M
ESPR:
$418.24M
NUVB:
$131.08M
ESPR:
$226.32M
NUVB:
-$139.03M
ESPR:
$77.18M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NUVB vs. ESPR — Risk / Return Rank
NUVB
ESPR
NUVB vs. ESPR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Nuvation Bio Inc. (NUVB) and Esperion Therapeutics, Inc. (ESPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NUVB | ESPR | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.02 | 2.15 | -1.13 |
Sortino ratioReturn per unit of downside risk | 1.95 | 3.14 | -1.19 |
Omega ratioGain probability vs. loss probability | 1.27 | 1.39 | -0.12 |
Calmar ratioReturn relative to maximum drawdown | 1.62 | 3.77 | -2.15 |
Martin ratioReturn relative to average drawdown | 2.97 | 9.52 | -6.55 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| NUVB | ESPR | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.02 | 2.15 | -1.13 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.23 | -0.34 | +0.11 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | -0.18 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.17 | -0.13 | -0.03 |
Drawdowns
NUVB vs. ESPR - Drawdown Comparison
The maximum NUVB drawdown since its inception was -93.39%, smaller than the maximum ESPR drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for NUVB and ESPR.
Loading charts...
Drawdown Indicators
| NUVB | ESPR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.39% | -99.37% | +5.98% |
Max Drawdown (1Y)Largest decline over 1 year | -57.55% | -53.19% | -4.36% |
Max Drawdown (3Y)Largest decline over 3 years | -58.19% | -80.94% | +22.75% |
Max Drawdown (5Y)Largest decline over 5 years | -92.88% | -97.23% | +4.35% |
Max Drawdown (10Y)Largest decline over 10 years | — | -99.10% | — |
Current DrawdownCurrent decline from peak | -67.60% | -97.28% | +29.68% |
Average DrawdownAverage peak-to-trough decline | -65.50% | -69.92% | +4.42% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 31.33% | 21.00% | +10.33% |
Volatility
NUVB vs. ESPR - Volatility Comparison
Nuvation Bio Inc. (NUVB) has a higher volatility of 18.34% compared to Esperion Therapeutics, Inc. (ESPR) at 1.30%. This indicates that NUVB's price experiences larger fluctuations and is considered to be riskier than ESPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NUVB | ESPR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.34% | 1.30% | +17.04% |
Volatility (6M)Calculated over the trailing 6-month period | 52.92% | 61.84% | -8.92% |
Volatility (1Y)Calculated over the trailing 1-year period | 91.39% | 94.06% | -2.67% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 75.57% | 91.97% | -16.40% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 73.03% | 84.71% | -11.68% |
Dividends
NUVB vs. ESPR - Dividend Comparison
Neither NUVB nor ESPR has paid dividends to shareholders.
Financials
NUVB vs. ESPR - Financials Comparison
This section allows you to compare key financial metrics between Nuvation Bio Inc. and Esperion Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NUVB vs. ESPR - Profitability Comparison
NUVB - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Nuvation Bio Inc. reported a gross profit of 77.61M and revenue of 83.23M. Therefore, the gross margin over that period was 93.3%.
ESPR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 80.10M. Therefore, the gross margin over that period was 0.0%.
NUVB - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Nuvation Bio Inc. reported an operating income of 3.88M and revenue of 83.23M, resulting in an operating margin of 4.7%.
ESPR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported an operating income of -6.58M and revenue of 80.10M, resulting in an operating margin of -8.2%.
NUVB - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Nuvation Bio Inc. reported a net income of 5.40M and revenue of 83.23M, resulting in a net margin of 6.5%.
ESPR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported a net income of -25.20M and revenue of 80.10M, resulting in a net margin of -31.5%.
Frequently Asked Questions
NUVB and ESPR have a correlation of 0.30, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NUVB has higher volatility (18.34%) compared to ESPR (1.30%). In terms of maximum drawdown, NUVB dropped -93.39% vs ESPR's -99.37%.
ESPR currently has the higher Sharpe Ratio (2.15 vs 1.02), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NUVB and ESPR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer